↓ Skip to main content

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Overview of attention for article published in Lancet Oncology, October 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
40 news outlets
twitter
48 X users
facebook
1 Facebook page

Citations

dimensions_citation
226 Dimensions

Readers on

mendeley
137 Mendeley